(MENAFN- America News Hour)
The global incretin-based drugs market is segmented by drug type into glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors; by administration method into oral drugs and injectable drugs and by regions. Incretin Based Drugs Market is anticipated to mask a CAGR of 3.4% during the forecast period i.e. 2018-2027.
Currently the global incretin based drugs market is observing a vibrant growth owing to increasing demand of diabetes control drugs in the market. Advances in pharmaceutical industry in the past few years and growing biologic hormonal explorations are projected to drive incretin based drugs market besides the wide range of functions of incretin based drugs in an immense range of body functioning such as lowering free fatty acid levels, improving insulin resistance, lowering body weight and more during the forecast period.
As a region with highly developed healthcare system, North America is panned to observe substantial growth in incretin based drugs market on account of rising incretin based drugs usage among the increasing diabetic type-2 suffering population. North America is estimated to be followed by Asia Pacific in terms of consumption due to expanding incretin based drugs requirements on the back of increasing geriatric population. Europe is expected to drive the demand and positively impact incretin-based drugs market growth over the forecast period owing to increasing incretin-based drugs application for improving β-cell performance and glucose profiles in patients.
Access Full Report, here:
Rise in Diabetic Population
World Diabetes Foundation has estimated that, there will be 438 million people with diabetes by 2030 which infers requirement for insulin management market will attend escalating diabetes population. Incretin based drugs display a promising market growth on account of high worldwide existence and occurrence of type-2 diabetes, wide-range research and development in technology for efficient insulin regulation and support from government and health care centers in making insulin management drugs available all over the world. According to World Health Organization (WHO) since 1980 till present, the worldwide occurrence of diabetes in adult population has increased from 4.7% to 8.5%.
Increasing Adoption of Sedentary Lifestyle
Increasing incidences of cardiovascular diseases, increasing geriatric population and high incidences of obesity due to adoption of sedentary lifestyle is anticipated to contribute significantly in driving the incretin based drugs market over the forecast period.
However, absence of insulin management in type-2 diabetes drugs from the market across the under-developed regions of the world along with concerns regarding efficacy of drugs, can impede incretin based drugs market growth while its obtainability would upsurge market size and demand in low and middle income countries.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter's five force model.
Get the inside scoop with Sample report-
This report also provides the existing competitive scenario of some of the key players of the global Incretin Based Drugs market which includes company profiling ofGlaxoSmithKline Plc., Boehringer Ingelheim GmbH., Merck & Co., Inc., Takeda Pharmaceutical Company Ltd., Sanofi S.A., AstraZeneca Plc., Eli Lilly and Company, Johnson & Johnson, Novartis AG and Nova Nordisk. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Incretin Based Drugsmarket that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
Contact Us
AJ Daniel
Email:
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]
Research Nester
Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.
MENAFN07012022004545010068ID1103502055
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.